Dr. Boley became a board-certified toxicologist in 2003, and has extensive expertise in drug development as well as the regulatory expectations for a variety of test article types and indications. He will be applying his breadth of experience to benefit Sinclair customers.
“Scott is an experienced toxicologist who is well-known in the industry,” said Guy Bouchard, DVM, president of Sinclair Research Center. “He is an expert in compound safety assessment with a deep regulatory understanding. Scott has advised sponsors with compound safety regulatory needs for the last 13 years and managed toxicology programs for 17 years. He will be an asset to our clients and their consultants.”